Continuing besifovir dipivoxil maleate versus switching from tenofovir disoproxil fumarate for treatment of chronic hepatitis B: Results of 192-week phase 3 trial

BACKGROUND/AIMS: Besifovir dipivoxil maleate (BSV), an acyclic nucleotide phosphonate, shows potent antiviral activity against hepatitis B virus. Our previous 48-week trial revealed that BSV has comparable antiviral efficacy to tenofovir disoproxil fumarate (TDF) and better safety profiles in terms...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Do Seon, Kim, Won, Ahn, Sang Hoon, Yim, Hyung Joon, Jang, Jae Young, Kweon, Young Oh, Cho, Yong Kyun, Kim, Yoon Jun, Hong, Gun Young, Kim, Dong Joon, Jung, Young Kul, Sohn, Joo Hyun, Lee, Jin-Woo, Park, Sung Jae, Lee, Byung Seok, Kim, Ju Hyun, Kim, Hong Soo, Yoon, Seung Kew, Kim, Moon Young, Lee, Kwan Sik, Lim, Young Suk, Lee, Wan Sik, Yang, Jin Mo, Kim, Kyun-Hwan, Han, Kwang-Hyub, Um, Soon Ho
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Association for the Study of the Liver 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8046633/
https://www.ncbi.nlm.nih.gov/pubmed/33493393
http://dx.doi.org/10.3350/cmh.2020.0307

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8046633/
https://www.ncbi.nlm.nih.gov/pubmed/33493393
http://dx.doi.org/10.3350/cmh.2020.0307

Ejemplares similares